Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir (Q33186873)

23 July 2017

title

Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir (English)

1 reference

https://api.crossref.org/works/10.1211/002235702739

23 July 2017

1 reference

pharmaceutical science

1 reference

29 December 2023

1 reference

https://api.crossref.org/works/10.1211/002235702739

29 December 2023

5

Jerold S Harmatz

1 reference

23 July 2017

6

David J Greenblatt

1 reference

23 July 2017

2

Lisa L von Moltke

1 reference

23 July 2017

4

Leah M Hesse

1 reference

23 July 2017

1

James L Weemhoff

1 reference

23 July 2017

Clemens Richert

3

1 reference

23 July 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12724045

29 December 2023

publication date

1 March 2003

1 reference

full work available at URL

23 July 2017

https://academic.oup.com/jpp/article-pdf/55/3/381/36781585/002235702739.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12724045

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1211%2F002235702739

29 December 2023

1 reference

https://api.crossref.org/works/10.1211/002235702739

http://academic.oup.com/jpp/article-pdf/55/3/381/36781585/002235702739.pdf

29 December 2023

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1211/002235702739

Journal of Pharmacy and Pharmacology

29 December 2023

published in

1 reference

23 July 2017

volume

55

1 reference

23 July 2017

issue

3

1 reference

23 July 2017

page(s)

381-386

1 reference

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

23 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Differential impairment of triazolam and zolpidem clearance by ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Lopinavir-Ritonavir: a new protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Effects of the antifungal agents on oxidative drug metabolism: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

In vitro approaches to predicting drug interactions in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Alprazolam-ritonavir interaction: implications for product labeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Interaction of sildenafil and indinavir when co-administered to HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F002235702739

Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors

21 January 2018

https://api.crossref.org/works/10.1211/002235702739

7

1 reference

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

29 December 2023

https://api.crossref.org/works/10.1211/002235702739

10

1 reference

In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification

29 December 2023

https://api.crossref.org/works/10.1211/002235702739

11

1 reference

In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions

29 December 2023

https://api.crossref.org/works/10.1211/002235702739

32

1 reference

29 December 2023

Identifiers

DOI

10.1211/002235702739

1 reference

23 July 2017

1 reference